Education is top priority as biosimilar mAbs enter the market
With the recent approval of Celltrion’s Truxima, all eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next frontier in the European biosimilars market, but warn that they may not achieve widespread uptake unless stakeholders can put doctors’ and patients’ biggest concerns to rest. Just what are those concerns? Who should lead the education initiative? What will it take to close the information gap?
Future of Biosimilars: Europe (2017) offers a step by step walkthrough of key developments in the European biosimilars market, as well as future challenges and opportunities. 11 respected industry experts weigh in on adoption and pending approvals, policy and regulation, the evolving role of payers and patients, and the urgent need for more and better education. You’ll also hear about promising future targets for manufacturers, noteworthy trends, upcoming events, and more.
Download now – and gain greater insight into the European biosimilars market.
Keep biosimilar adoption trending up. Download this report to find out how.
Find out where to focus your education initiatives. Download this report now.
The 11 industry experts we interviewed for this report either have direct experience in the development and/or commercialisation of biosimilars, or are considered experts in the field. To enable them to express candid views, some respondents have chosen to remain anonymous.
“We believe the number one priority in any educational effort is to bring biosimilar science to the patients and the medical community in a simple, understandable way, making them aware of what is possible using modern technology.”
Rüdiger Jankowsky – Managing Director, Cinfa Biotech
“Education can rapidly remove a lot of the concerns that physicians, patients, payers and pharmacists have about using biosimilars. It is important to take all stakeholders on this journey.”
Carol Lynch – Global Head of Biopharmaceuticals, Sandoz
“Companies will provide information, but when the payers, patient groups and medical societies take ownership, there is more trust in the information. Regulators could take a role, but I think they do quite a good job now with all of the publications that emerge from the EMA and EC [European Commission]. Critically, all of the information that gets published needs to be understandable by the average person.”
Carsten Brockmeyer – CEO, Formycon
“I think people can learn from what happened with generics in the 1980s, how they were faced resistance and then eventually got accepted. Now almost 90 percent of drugs prescribed are substituted generic drugs.”
Rakesh Dixit – VP R&D, MedImmune
Hear more from the experts – order today.
Order now and start planning your stakeholder education strategy.
This critical intelligence is available for immediate download — order your copy now
Need more information? Contact a consultant for an executive summary and sample pages from the report.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved